Detalles de la búsqueda
1.
Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis.
Lancet Oncol
; 25(6): 760-769, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38754451
2.
Treatment methods for cervical intraepithelial neoplasia in England: A cost-effectiveness analysis.
BJOG
; 2024 Apr 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38659133
3.
Prevalence, diagnostic delay and economic burden of endometriosis and its impact on quality of life: results from an Eastern Mediterranean population.
Eur J Public Health
; 34(2): 244-252, 2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38070492
4.
Research evaluating the effectiveness of dementia interventions in low- and middle-income countries: A systematic mapping of 340 randomised controlled trials.
Int J Geriatr Psychiatry
; 38(7): e5965, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37430439
5.
Price changes and within-class competition of cancer drugs in the USA and Europe: a comparative analysis.
Lancet Oncol
; 23(4): 514-520, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35271804
6.
Comparative effectiveness and risk of preterm birth of local treatments for cervical intraepithelial neoplasia and stage IA1 cervical cancer: a systematic review and network meta-analysis.
Lancet Oncol
; 23(8): 1097-1108, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35835138
7.
Coverage of New Drugs in Medicare Part D.
Milbank Q
; 100(2): 562-588, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35502786
8.
Generating comparative evidence on new drugs and devices after approval.
Lancet
; 395(10228): 998-1010, 2020 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32199487
9.
Generating comparative evidence on new drugs and devices before approval.
Lancet
; 395(10228): 986-997, 2020 03 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32199486
10.
Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
Heart Fail Rev
; 25(2): 161-171, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31364027
11.
Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Milbank Q
; 98(4): 1219-1256, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33021339
12.
Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
Value Health
; 23(3): 319-327, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32197727
13.
NICE's evaluations of medicines authorized by EMA with conditional marketing authorization or under exceptional circumstances.
Int J Technol Assess Health Care
; : 1-8, 2020 Jun 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-32638664
14.
Assessment of technical errors and validation processes in economic models submitted by the company for NICE technology appraisals.
Int J Technol Assess Health Care
; : 1-6, 2020 Jul 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32618536
15.
How does exercise treatment compare with antihypertensive medications? A network meta-analysis of 391 randomised controlled trials assessing exercise and medication effects on systolic blood pressure.
Br J Sports Med
; 53(14): 859-869, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-30563873
16.
How good is "evidence" from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs?
Annu Rev Pharmacol Toxicol
; 55: 169-89, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-25149917
17.
Specialty Drugs - A Distinctly American Phenomenon.
N Engl J Med
; 382(23): 2179-2181, 2020 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32492301
18.
The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Clin Trials
; 15(3): 219-229, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29871509
19.
Association Between Preapproval Confirmatory Trial Initiation and Conversion to Traditional Approval or Withdrawal in the FDA Accelerated Approval Pathway.
JAMA
; 329(9): 760-761, 2023 03 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-36705931
20.
Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval.
Milbank Q
; 95(2): 261-290, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28589600